US6087393A - Stabilized vitamin C formulations - Google Patents

Stabilized vitamin C formulations Download PDF

Info

Publication number
US6087393A
US6087393A US09/329,608 US32960899A US6087393A US 6087393 A US6087393 A US 6087393A US 32960899 A US32960899 A US 32960899A US 6087393 A US6087393 A US 6087393A
Authority
US
United States
Prior art keywords
glycol
solution
ascorbic acid
mixed
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/329,608
Inventor
Rajiv Mathur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGEN Inc
Original Assignee
IGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGEN Inc filed Critical IGEN Inc
Priority to US09/329,608 priority Critical patent/US6087393A/en
Assigned to IGEN, INC. reassignment IGEN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATHUR, RAJIV
Assigned to FLEET CAPITAL CORPORATION reassignment FLEET CAPITAL CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IGEN, INC
Assigned to AMERICAN CAPITAL STRATEGIES, LTD. reassignment AMERICAN CAPITAL STRATEGIES, LTD. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IGEN, INC.
Priority to US09/570,995 priority patent/US6211231B1/en
Priority to PCT/US2000/015061 priority patent/WO2000076547A1/en
Priority to CA002376303A priority patent/CA2376303C/en
Priority to EP00936442A priority patent/EP1194169B1/en
Priority to DE60021727T priority patent/DE60021727D1/en
Priority to AU51757/00A priority patent/AU5175700A/en
Priority to AT00936442T priority patent/ATE300958T1/en
Publication of US6087393A publication Critical patent/US6087393A/en
Application granted granted Critical
Assigned to IGEN, INC. reassignment IGEN, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: FLEET CAPITAL CORPORATION
Assigned to LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P., LIFE SCIENCES OPPORTUNITIES FUND II, L.P. reassignment LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P. SECURITY AGREEMENT Assignors: IGI LABORATORIES, INC., IMMUNOGENETICS, INC.
Assigned to IMMUNOGENETICS, INC., IGI LABORATORIES INC. reassignment IMMUNOGENETICS, INC. RELEASE OF SECURITY AGREEMENT RECORDED 3/16/09, R/F 02239/0570 Assignors: LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P., LIFE SCIENCES OPPORTUNITIES FUND II, L.P.
Assigned to IGEN, INC. reassignment IGEN, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN CAPITAL, LTD. (FORMERLY NAMED AMERICAN CAPITAL STRATEGIES, LTD.) AS GRANTEE
Assigned to CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT reassignment CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT NOTICE OF GRANT Assignors: IGEN, INC., TELIGENT PHARMA, INC., TELIGENT, INC.
Assigned to IGEN, INC., TELIGENT PHARMA, INC, TELIGENT, INC reassignment IGEN, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CANTOR FITZGERALD SECURITIES
Assigned to ACF FINCO I LP reassignment ACF FINCO I LP SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IGEN, INC., TELIGENT, INC
Assigned to ARES CAPITAL CORPORATION reassignment ARES CAPITAL CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IGEN, INC., TELIGENT, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals

Definitions

  • the invention also features a solution containing free 1-ascorbic acid stabilized from oxidation in the mixed glycol carrier.
  • the mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol, and stabilizing and solubility assisting agents as well. These additional agents may include diisopropyl adipate, myristyl ether propionate, Sepigel 305, isodecyl neopentonate, transcutol, lactil, or mixtures thereof.
  • the preferred range of the propylene glycol in the mixed carrier is 25-80% by weight, with the butylene glycol being 5-30% by weight.
  • a mixed glycol solution of this type can provide a stable solution of 5% or even higher levels of ascorbic acid without oxidative degradation.
  • the dispersion may also include a cosmetically, dermatalogically or pharmaceutically acceptable carrier.
  • the invention features a method of stabilizing free 1-ascorbic acid from oxidation by dispersing the free 1-ascorbic acid in a mixed glycol carrier and a solution containing the ascorbic acid in the mixed glycol solution
  • the mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol, and stabilizing and solubility assisting agents as well.
  • additional agents may include diisopropyl adipate, myristyl ether propionate, polyacrylamide, isodecyl neopentonate, diethylene glycol monoethyl ether, lactil, or mixtures thereof.

Abstract

The invention features a method of stabilizing free 1-ascorbic acid from oxidation by dispersing the free 1-ascorbic acid in a mixed glycol carrier and a solution containing the ascorbic acid in the mixed glycol solution. The mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol , and stabilizing and solubility assisting agents as well.

Description

BACKGROUND OF THE INVENTION
For many years, researchers have been investigating methods for stabilizing 1-ascorbic acid (vitamin C), due to its beneficial properties. Indeed, 1-ascorbic acid has many known biological functions, such as the stimulation of collagen synthesis, the strengthening of skin tissue against external attack (UV radiation, pollution), depigmentation, activity against free radicals and the compensation for vitamin E deficiency. Some of these beneficial properties have been reported by England and Seifter in the article "The biochemical functions of ascorbic acid" (Ann. Rev. Nutri. (1986) 6:365-406).
However, due to its alpha-keto lactone structure, ascorbic acid is very sensitive to the influence of environmental parameters such as light, oxygen, and water. An unavoidable degradation of ascorbic acid in solution occurs over time due to its pH and the presence of trace metals.
This problem has been addressed in a variety of ways in the art. In order to reduce or delay the degradation of ascorbic acid in solution, U.S. Pat. No. 5,140,043 recommends stabilization by introducing ascorbic acid into aqueous-alcoholic solutions, formed of at least 80% water and having a pH below 3.5. These solutions are not usable in the cosmetic and/or pharmaceutical field because of a combination of pH, drying of the skin by the alcohol, and a lack of aesthetic "feel." Indeed, repeated application of these solutions may disrupt the equilibrium of the skin and may in particular irritate, or even burn, the skin.
Others have tried different ways to produce a stable ascorbic acid solution. B. R. Hajratwala, in "Stability of ascorbic acid", published in the Revue Sciences Pharmaceutiques on Mar. 15, 1905, discloses that ascorbic acid may be stabilized as an acidic aqueous solution by adding an oxyethylenated sorbitan ester surface-active agent. In particular, Hajratwala states that at pH3.4 and 25° C., the addition of this agent reduced the rate of oxidation, and thus the rate of degradation, of ascorbic acid in solution. Hajratwala also discloses the use of a chelating agent such as ethylenediaminetetraacetic acid (EDTA) and packaging under nitrogen, in the absence of light, in order to enhance the stability of the aqueous ascorbic acid solution. However, such an acidic aqueous solution, applied to the skin, has the same drawbacks as those described above for acidic aqueous-alcoholic solutions. Furthermore, the stabilization obtained is still insufficient. Other ways of stabilizing ascorbic acid have been proposed, in particular by a coating technique (FR-A-1,600,826) or by granulation of ascorbic acid (JP-A-53-127,819) for the agri-foods industry.
These techniques, while providing some stability, are, on the one hand, expensive and may, on the other hand, damage the ascorbic acid, for example during heating. Generally, these techniques lead to compositions of poor cosmetic acceptability, as in the case of granules. Consequently, none of the previous proposals have made it possible to overcome the technical problem associated with the instability of ascorbic acid in solution, in a form which is suitable for the cosmetic and/or dermatological fields and at a cost which is compatible with industrial requirements.
Accordingly, an object of the invention is to provide a method and formulation containing ascorbic acid that has improved stability.
Another object of the invention is to provide a method and formulation containing ascorbic acid that has proper aesthetic qualities for use in a dermatological or cosmetic product.
A further object of the invention is to provide a method and formulation containing ascorbic acid that is relatively inexpensive while providing the desire stability and aesthetic properties.
These and other objects and features of the invention will be apparent from the detailed description and the claims.
SUMMARY OF THE INVENTION
The invention pertains, at least in part, to a method of stabilizing free 1-ascorbic acid from oxidation by dispersing the free 1-ascorbic acid in a mixed glycol carrier. This mixed glycol carrier provides both high levels of solubility and stability at a relatively low price. The mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol, and stabilizing and solubility assisting agents as well. These additional agents may include diisopropyl adipate, myristyl ether propionate, polyacrylamide (e.g., Sepigel 305), isodecyl neopentonate, diethylene glycol monoethyl ether (e.g., transcutol), lactil (a mixture of sodium lactate, sodium pyrrolidone carboxylic acid, urea, niacinamide, inositol, lactic acid, sodium benzoate, and hydrolized animal protein sold by Goldschmidt A. G.), or mixtures thereof.
The invention also features a solution containing free 1-ascorbic acid stabilized from oxidation in the mixed glycol carrier. The mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol, and stabilizing and solubility assisting agents as well. These additional agents may include diisopropyl adipate, myristyl ether propionate, Sepigel 305, isodecyl neopentonate, transcutol, lactil, or mixtures thereof. The preferred range of the propylene glycol in the mixed carrier is 25-80% by weight, with the butylene glycol being 5-30% by weight. A mixed glycol solution of this type can provide a stable solution of 5% or even higher levels of ascorbic acid without oxidative degradation. The dispersion may also include a cosmetically, dermatalogically or pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION
The invention features a method of stabilizing free 1-ascorbic acid from oxidation by dispersing the free 1-ascorbic acid in a mixed glycol carrier and a solution containing the ascorbic acid in the mixed glycol solution The mixed glycol carrier contains a mixture of at least propylene glycol and butylene glycol, but may contain other glycols such as polyethylene glycol, and stabilizing and solubility assisting agents as well. These additional agents may include diisopropyl adipate, myristyl ether propionate, polyacrylamide, isodecyl neopentonate, diethylene glycol monoethyl ether, lactil, or mixtures thereof. The preferred range of the propylene glycol in the mixed carrier is 25-80% by weight, with the butylene glycol being 5-30% by weight. A mixed glycol solution of this type can provide a stable solution of 5% or even higher levels of ascorbic acid without oxidative degradation.
The following, non-limiting examples help in illustrating the invention.
EXEMPLIFICATION OF THE INVENTION Example 1
In this example, solutions were made which incorporated 1-ascorbic acid. This study was performed to test the relative feasibility of incorporating stabilized free 1-ascorbic acid into a solution. The initial solution was made according to the Formulation given in Table 1.
              TABLE 1                                                     
______________________________________                                    
Compound     Weight of components in grams                                
______________________________________                                    
L-Ascorbic Acid                                                           
             5.0                                                          
Propylene Glycol                                                          
             94.0                                                         
Sepigel 305  1.0                                                          
______________________________________                                    
The 1-ascorbic acid was obtained from Sigma. The propylene glycol was obtained fromOlin Chemicals. Sepigel 305 consists of polyacrylamide, C13 C14 isoparaffin and laureth-7. An overhead mixer was used to combine the Sepigel and the propylene glycol. The mixture was then heated to approximately 50° C. and stirred 3 hours to disperse the Sepigel. The 1-ascorbic acid was then added and the mixture was is stirred for 30 minutes. The resulting mixture had a pH of 2.97. However, this solution did not provide the stability or aesthetics required for a cosmetic product.
Example 2
In this experiment, the solution was altered to increase he stability and improve the aesthetics of the product. The same procedure referenced above was used to make these solutions. The formulations of these solutions of this example are given in Table 2.
              TABLE 2                                                     
______________________________________                                    
                   Weight                                                 
                   of components in grams                                 
Compound           A      B       C    D                                  
______________________________________                                    
Polyethylene Glycol                                                       
                   --     --      10.0 --                                 
Butylene Glycol    44.5   40      40.0 46.0                               
Propylene Glycol   44.5   35      30.0 35.0                               
Diisopropyl Adipate (Ceraphyl-230)                                        
                   5.0    10      10.0 10.0                               
Myristyl Ether Propionate                                                 
                   --     5.0     --   --                                 
Sepigel 305        1.0    1.0     1.0  1.0                                
1-ascorbic acid    5.0    5.0     5.0  5.0                                
______________________________________                                    
Each solution was made by initially mixing Sepigel 305 with the propylene glycol at 55-60° C. until the solution became clear. The remaining compounds were subsequently added and each solution was then stirred. After prolonged stirring, the resulting solution was uniformly hazy, except for `A.` `A` was clear with a good viscosity. After adding the butylene glycol (specifically 1,3 butylene glycol, a material often used in cosmetics)and PEG-200, however, the viscosity of the each solution decreased. After adding all the ingredients, `D` solution was determined to be superior aesthetically. The non-glycol components are primarily stabilizing elements and can be replaced with similar polymer components.
Example 3
In order to improve the `feel` and clarity of the solution, the formulations outlined in Table 3 were attempted. The solutions were made in the same method as outlined in Example 2.
              TABLE 3                                                     
______________________________________                                    
                    Weight                                                
                    of components in grams                                
Compound            A        B      C                                     
______________________________________                                    
Butylene Glycol     35       20     10                                    
Propylene Glycol    39       44     60                                    
Diisopropyl Adipate (Ceraphyl-230)                                        
                    20       20     15                                    
Sepigel 305         1.0      1.0    1.0                                   
1-ascorbic acid     5.0      5.0    5.0                                   
______________________________________                                    
The propylene glycol was heated to 55-60° C. and the Sepigel 305 was subsequently added. The solution was then stirred by an overhead mixer until it was clear. The remaining components of the solutions were then added and stirred without additional heating. All of the resulting solutions were hazy. To `A,` 1.5% Polysorbate 80 was added unsuccessfully to improve the clarity of the solutions. `C` was the least hazy.
Example 4
In order improve the clarity, the solutions of the formulations outlined in Table 4 were made. The propylene glycol solution was a 1% solution of Sepigel 305 in propylene glycol.
              TABLE 4                                                     
______________________________________                                    
                  Weight of components in grams                           
Compound          A       B     C     D   E                               
______________________________________                                    
Propylene Glycol Solution                                                 
                  75      85    80    70  80                              
Butylene Glycol   --      --    10    10                                  
Diisopropyl Adipate (Ceraphyl-230)                                        
                  20      --    10    10                                  
Myristyl Ether Propionate (PPG-2)                                         
                  --      10    --                                        
Isodecyl Neopentonate (DUB ICI)                                           
                  --      --    --        10                              
1-ascorbic acid    5       5     5     5   5                              
______________________________________                                    
The solutions were made by adding the remaining components to the propylene glycol solution. All of the resulting solutions were somewhat hazy. In mixtures `B` and `E,` the ester components separated out from the other components of the solution. When heated to 50° C., the solutions remained the same. Mixture `D` had the lightest "feel." It is clear that the combination of propylene glycol and butylene glycol provides advantageous results compared to the solutions lacking the butylene glycol.
Example 5
In the following experiment, transcutol (diethylene glycolmonoethyl ether) was incorporated into the solution mixture. The propylene glycol solution was the same as in Example 4. The formulations of the solutions are outlined in Table 5.
              TABLE 5                                                     
______________________________________                                    
                       Weight of com-                                     
                       ponents in grams                                   
Compound               A      B                                           
______________________________________                                    
Propylene Glycol Solution                                                 
                       65     60                                          
Butylene Glycol        10     10                                          
Diisopropyl Adipate (Ceraphyl-230)                                        
                       15     10                                          
transcutol             --     10                                          
1-ascorbic acid        5.0    5.0                                         
______________________________________                                    
The propylene glycol solution was mixed with the remaining ingredients, as discussed in the preceding Examples. As solution `A` cooled to room temperature, it became cloudy. When it was reheated, the mixture became clear. Solution `B` remained clear throughout cooling and reheating. Accordingly, the addition of transcutol appears to provide some advantage.
Example 6
In the following example, the percentage of Sepigel 305 in the propylene glycol solution was increased to 1.25% to improve the clarity of the solutions. The procedure was identical to the one outlined in the preceding Example. The formulations of the solutions are given in Table 6.
              TABLE 6                                                     
______________________________________                                    
                    Weight                                                
                    of components in grams                                
Compound            A        B     C                                      
______________________________________                                    
Propylene Glycol Solution                                                 
                    65       60    50                                     
1,3 Butylene Glycol 15       10    20                                     
Diisopropyl Adipate (Ceraphyl-230)                                        
                    10       10    15                                     
1-ascorbic acid     5        5     5                                      
transcutol          5        10    5                                      
______________________________________                                    
After mixing the remaining components with the propylene glycol solution, `A` and `C` were slightly hazy and `B` was clear. Aesthetically, `C` had a "light" feel. Both `A` and `B` were shiny and light.
Example 7
In this example, additional components were added to the solutions. The formulation of the solutions is outlined in Table 7. The propylene glycol solution contained 1.25% Sepigel 305.
              TABLE 7                                                     
______________________________________                                    
                   Weight of components in grams                          
Compound           A      B        C   D                                  
______________________________________                                    
Propylene Glycol Solution                                                 
                   70     70       60  60                                 
1,3 Butylene Glycol                                                       
                   10     10       15  15                                 
Diisopropyl Adipate (Ceraphyl-230)                                        
                   10     10       15  15                                 
DC 344             --      5       --  --                                 
Lactil             5      --       --  --                                 
1-ascorbic acid    5.0    5.0      10  5.0                                
______________________________________                                    
The 1-ascorbic acid was placed in the propylene glycol solution and heated to approximately 50° C. The mixture was then stirred for about 10 minutes, or until the acid dissolved. The remaining components were then added.
`A` became hazy after adding lactil. The addition of Span 80 (Sorbitan monooleate) did not clear the solution. `B` became hazy after the addition of DC 344 (Cyclomethicone). The addition of Span 80 did not clarify solution B either. `C` and `D` were clear at elevated temperatures, but they became cloudy once they reached room temperature.
Example 8
In this example, the pH of the solutions was increased by adding triethanolamine, magnesium ascorbyl phosphate, and morpholine. The formulations of the solutions are given in the table below. The propylene glycol solution contain 1.25% Sepigel 305.
              TABLE 8                                                     
______________________________________                                    
                      Weight of com-                                      
                      ponents in grams                                    
Compound              A      B                                            
______________________________________                                    
Propylene Glycol Solution                                                 
                      75     65                                           
Butylene Glycol       10     15                                           
Diisopropyl Adipate (Ceraphyl-230)                                        
                      10     10                                           
transcutol            --     5                                            
1-ascorbic acid       5.0    5.0                                          
______________________________________                                    
L-ascorbic acid was added to the propylene glycol solution and stirred for fifteen minutes. The remaining components were then added. The pH of both solutions was initially 3.01. After the addition of 1 ml triethanolamine, both solutions became hazy. When morpholine was added to another sample, both solutions became hazy. Both sodium hydroxide and magnesium ascorbyl phosphate were not soluble in the solutions.
At room temperature, both `A` and `B` remained clear for seven months. At 40° C., both `A` and `B` started to yellow after about four months. At 50° C., both samples turned yellow after less than a month.
To yet another sample of `A,` an additional 5% of 1-ascorbic acid was added. After being warmed slightly and stirred for fifteen minutes, the solution became clear. The pH of the solution was 2.86. At 50° C., 40° C., and room temperature, `A` was clear. When chilled in the refrigerator, `A` became hazy. After one month at room temperature, the samples were slightly yellowish. At 50° C. after one month, `A` was very discolored.
To a sample of `B,` an additional 5% of 1-ascorbic acid was added at 50° C. The solution remained clear at 50° C., 40° C., and at room temperature. When chilled, `B` became cloudy. After one month at room temperature, the samples were slightly yellowish. At 50° C. after one month, `B` was very discolored.
EQUIVALENTS
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims. The contents of all references, issued patents, and published patent applications cited throughout this application are hereby incorporated by reference.

Claims (18)

What is claimed is:
1. A method of stabilizing free 1-ascorbic acid from oxidation by dispersing said free 1-ascorbic acid in a mixed glycol carrier, said mixed glycerol carrier comprising propylene glycol and butylene glycol, and wherein the dispersion further comprises a stabilizer selected from the group consisting of diisopropyl adipate, myristyl ether propionate, polyacrylamide, isodecyl neopentonate, diethylene glycol monoethyl ether, lactil, and mixtures thereof.
2. The method of claim 1 wherein said mixed glycol carrier comprises 25-80% by weight propylene and 5-30% by weight butylene glycol.
3. The method of claim 1, wherein the dispersion is comprised of about 2% to about 15% free 1-ascorbic acid by weight.
4. The method of claim 1, wherein said mixed glycol carrier further comprises polyethylene glycol.
5. The method of claim 1, wherein said mixed glycol carrier further comprises a cosmetically, dermatalogically or pharmaceutically acceptable carrier.
6. A solution for topical use comprising 1-ascorbic acid in a mixed glycol carrier containing propylene glycol, butylene glycol, and a stabilizer selected from the group consisting of diisopropyl adipate, myristyl ether propionate, polyacrylamide, isodecyl neopentonate, diethylene glycol monoethyl ether, lactil, and mixtures thereof.
7. The solution of claim 6 where said mixed glycol carrier comprises 25-80% by weight propylene glycol and 5-30% by weight butylene glycol.
8. The solution of claim 6 wherein said mixed glycol carrier further comprises polyethylene glycol.
9. The solution of claim 6 wherein said mixed glycol carrier comprises about 75% propylene glycol solution and about 10% butylene glycol, and said solution further comprises about 10% diisopropyl adipate, and about 5% free 1-ascorbic acid.
10. The solution of claim 6 wherein said mixed glycol carrier comprises about 65% propylene glycol solution and about 15% butylene glycol, and said solution further comprises about 10% diisopropyl adipate, about 5% diethylene glycol monoethyl ether, and about 5% free 1-ascorbic acid.
11. The solution of claim 6 wherein said mixed glycol carrier comprises about 60% propylene glycol solution and about 15% 1,3 butylene glycol, and said solution further comprises about 10% diisopropyl adipate, about 10% diethylene glycol monoethyl ether, and about 5% free 1-ascorbic acid.
12. The solution of claim 6 wherein said mixed glycol carrier comprises about 50% propylene glycol solution and about 20% 1,3 butylene glycol, and said solution further comprises about 15% diisopropyl adipate, about 5% diethylene glycol monoethyl ether, and about 5% free 1-ascorbic acid.
13. The solution of claim 6 wherein said mixed glycol carrier comprises about 65% propylene glycol solution and about 10% 1,3 butylene glycol, and said solution further comprises about 15% diisopropyl adipate, and about 5% free 1-ascorbic acid.
14. The solution of claim 6 wherein said mixed glycol carrier comprises about 60% propylene glycol solution and about 10% 1,3 butylene glycol, and said solution further comprises about 10% diisopropyl adipate, about 10% diethylene glycol monoethyl ether, and about 5% free 1-ascorbic acid.
15. The solution of claim 6 wherein said mixed glycol carrier comprises about 70% propylene glycol solution and about 10% butylene glycol, and said solution further comprises about 10% diisopropyl adipate, about 5% lactil and about 5% 1-ascorbic acid.
16. The solution of claim 6 wherein said mixed glycol carrier comprises about 70% propylene glycol solution and about 10% butylene glycol, and said solution further comprises about 10% diisopropyl adipate, about 5% Cyclomethicone and about 5% 1-ascorbic acid.
17. The solution of claim 6 wherein said mixed glycol carrier comprises about 60% propylene glycol solution and about 15% butylene glycol, and said solution further comprises about 15% diisopropyl adipate, and about 10% 1-ascorbic acid.
18. The solution of claim 6 wherein said mixed glycol carrier comprises about 65% propylene glycol solutions and about 15% butylene glycol, and said solution further comprises about 15% diisopropyl adipate, and about 5% 1-ascorbic acid.
US09/329,608 1999-06-10 1999-06-10 Stabilized vitamin C formulations Expired - Lifetime US6087393A (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US09/329,608 US6087393A (en) 1999-06-10 1999-06-10 Stabilized vitamin C formulations
US09/570,995 US6211231B1 (en) 1999-06-10 2000-05-15 Stabilized vitamin C formulations
AT00936442T ATE300958T1 (en) 1999-06-10 2000-05-31 STABILIZED VITAMIN C FORMULATIONS
AU51757/00A AU5175700A (en) 1999-06-10 2000-05-31 Stabilized vitamin c formulations
PCT/US2000/015061 WO2000076547A1 (en) 1999-06-10 2000-05-31 Stabilized vitamin c formulations
CA002376303A CA2376303C (en) 1999-06-10 2000-05-31 Stabilized vitamin c formulations
EP00936442A EP1194169B1 (en) 1999-06-10 2000-05-31 Stabilized vitamin c formulations
DE60021727T DE60021727D1 (en) 1999-06-10 2000-05-31 STABILIZED VITAMIN C FORMULATIONS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/329,608 US6087393A (en) 1999-06-10 1999-06-10 Stabilized vitamin C formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/570,995 Continuation US6211231B1 (en) 1999-06-10 2000-05-15 Stabilized vitamin C formulations

Publications (1)

Publication Number Publication Date
US6087393A true US6087393A (en) 2000-07-11

Family

ID=23286209

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/329,608 Expired - Lifetime US6087393A (en) 1999-06-10 1999-06-10 Stabilized vitamin C formulations
US09/570,995 Expired - Lifetime US6211231B1 (en) 1999-06-10 2000-05-15 Stabilized vitamin C formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/570,995 Expired - Lifetime US6211231B1 (en) 1999-06-10 2000-05-15 Stabilized vitamin C formulations

Country Status (7)

Country Link
US (2) US6087393A (en)
EP (1) EP1194169B1 (en)
AT (1) ATE300958T1 (en)
AU (1) AU5175700A (en)
CA (1) CA2376303C (en)
DE (1) DE60021727D1 (en)
WO (1) WO2000076547A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002019972A2 (en) * 2000-09-08 2002-03-14 Vivier Canada Inc. Stabilized ascorbic acid solutions
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
US20060167064A1 (en) * 2002-12-26 2006-07-27 Seth Pyare L Pharmaceutical liquid composition containing pyridone derivative
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
JP2007161635A (en) * 2005-12-13 2007-06-28 Kanebo Ltd Two layer separating type cosmetic
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
KR100836032B1 (en) * 2002-03-26 2008-06-09 (주)아모레퍼시픽 Multi-hollow polymer microcapsules containing L-ascorbic acid, the process for preparation of the same and the cosmetic composition thereof
US20100260695A1 (en) * 2009-04-09 2010-10-14 Mary Kay Inc. Combination of plant extracts to improve skin tone
GB2482794A (en) * 2010-08-14 2012-02-15 Chatfield Pharmaceuticals Ltd Formulations comprising vitamin C in glycol carrier
JP2012162468A (en) * 2011-02-04 2012-08-30 Mt Cosmetics Kk Solution blended with ascorbic acid and method for producing the solution
EP2010144B1 (en) * 2006-04-13 2015-10-14 Reckitt Benckiser (Brands) Limited Antioxidant compositions for reducing odor in warming lubricant compositions
WO2019189742A1 (en) * 2018-03-30 2019-10-03 ロート製薬株式会社 Composition for external application containing ascorbic acid and/or salt thereof
US11793813B2 (en) 2016-02-19 2023-10-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253137A1 (en) 2000-04-04 2001-10-15 Amarillo Biosciences, Inc. Composition and method for promoting oral health
US20070077261A1 (en) * 2005-10-03 2007-04-05 Jerry Zhang Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers
DE102013018573A1 (en) 2013-10-31 2015-05-21 Stephan Teichmann Oxidation-stable preparation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1600826A (en) * 1967-06-30 1970-08-03 Stabilisation of ascorbic acid with a coating of org
JPS53127819A (en) * 1977-04-12 1978-11-08 Riken Vitamin Co Ltd Stabilization of l-asocorbic acid and its salt
US5002761A (en) * 1988-05-02 1991-03-26 Henkel Kommanditgesellschaft Auf Aktien Hair treatment compositions containing natural ingredients
US5035895A (en) * 1988-01-22 1991-07-30 Eisai Co., Ltd. Emulsified and solubilized pharmaceutical preparation
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5552446A (en) * 1994-02-04 1996-09-03 L'oreal Emulsion containing stabilized ascorbic acid, cosmetic treatment process using it and uses thereof
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
US5843411A (en) * 1997-02-06 1998-12-01 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983392A (en) 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4983382A (en) * 1987-01-27 1991-01-08 Avon Products, Inc. Cosmetic preparation incorporating stabilized ascorbic acid
US5750123A (en) 1996-06-28 1998-05-12 Chesebrough-Pond's Co., Division Of Conopco, Inc. Vitamin C delivery system
US6162419A (en) 1996-11-26 2000-12-19 Nicholas V. Perricone Stabilized ascorbyl compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1600826A (en) * 1967-06-30 1970-08-03 Stabilisation of ascorbic acid with a coating of org
JPS53127819A (en) * 1977-04-12 1978-11-08 Riken Vitamin Co Ltd Stabilization of l-asocorbic acid and its salt
US5035895A (en) * 1988-01-22 1991-07-30 Eisai Co., Ltd. Emulsified and solubilized pharmaceutical preparation
US5002761A (en) * 1988-05-02 1991-03-26 Henkel Kommanditgesellschaft Auf Aktien Hair treatment compositions containing natural ingredients
US5140043A (en) * 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5552446A (en) * 1994-02-04 1996-09-03 L'oreal Emulsion containing stabilized ascorbic acid, cosmetic treatment process using it and uses thereof
US5587149A (en) * 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
US5843411A (en) * 1997-02-06 1998-12-01 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
England et al., "The biochemical functions of ascorbic acid," Ann. Rev. Nutr., 6:365-406 (1986).
England et al., The biochemical functions of ascorbic acid, Ann. Rev. Nutr. , 6:365 406 (1986). *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125482A1 (en) * 2000-09-08 2008-05-29 Ghislain Vivier Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same
WO2002019972A3 (en) * 2000-09-08 2002-09-06 Vivier Canada Inc Stabilized ascorbic acid solutions
US20060029687A1 (en) * 2000-09-08 2006-02-09 Ghislain Vivier Stabilized ascorbic acid solutions; use thereof; process for their obtention; and formulations comprising the same
WO2002019972A2 (en) * 2000-09-08 2002-03-14 Vivier Canada Inc. Stabilized ascorbic acid solutions
US9687471B2 (en) 2000-09-08 2017-06-27 Vivier Canada Inc. Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same
US8053469B2 (en) 2000-09-08 2011-11-08 Vivier Canada Inc. Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same
JP2007238625A (en) * 2000-09-08 2007-09-20 Vivier Canada Inc Stabilized ascorbic acid solution; use thereof; process for its preparation; and formulation comprising the same
US7342045B2 (en) 2000-09-08 2008-03-11 Ghislain Vivier Stabilized ascorbic acid solutions; use thereof; process for their obtention; and formulations comprising the same
KR100836032B1 (en) * 2002-03-26 2008-06-09 (주)아모레퍼시픽 Multi-hollow polymer microcapsules containing L-ascorbic acid, the process for preparation of the same and the cosmetic composition thereof
US20060167064A1 (en) * 2002-12-26 2006-07-27 Seth Pyare L Pharmaceutical liquid composition containing pyridone derivative
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
JP2007161635A (en) * 2005-12-13 2007-06-28 Kanebo Ltd Two layer separating type cosmetic
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
EP2010144B1 (en) * 2006-04-13 2015-10-14 Reckitt Benckiser (Brands) Limited Antioxidant compositions for reducing odor in warming lubricant compositions
US20100260695A1 (en) * 2009-04-09 2010-10-14 Mary Kay Inc. Combination of plant extracts to improve skin tone
GB2482794A (en) * 2010-08-14 2012-02-15 Chatfield Pharmaceuticals Ltd Formulations comprising vitamin C in glycol carrier
JP2012162468A (en) * 2011-02-04 2012-08-30 Mt Cosmetics Kk Solution blended with ascorbic acid and method for producing the solution
US11793813B2 (en) 2016-02-19 2023-10-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
WO2019189742A1 (en) * 2018-03-30 2019-10-03 ロート製薬株式会社 Composition for external application containing ascorbic acid and/or salt thereof
CN111971043A (en) * 2018-03-30 2020-11-20 日本乐敦制药株式会社 Ascorbic acid and/or external composition containing salt thereof
JPWO2019189742A1 (en) * 2018-03-30 2021-04-01 ロート製薬株式会社 Topical composition containing ascorbic acid and / or a salt thereof

Also Published As

Publication number Publication date
ATE300958T1 (en) 2005-08-15
US6211231B1 (en) 2001-04-03
CA2376303C (en) 2008-07-29
EP1194169A1 (en) 2002-04-10
WO2000076547A1 (en) 2000-12-21
EP1194169B1 (en) 2005-08-03
DE60021727D1 (en) 2005-09-08
AU5175700A (en) 2001-01-02
CA2376303A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
US6087393A (en) Stabilized vitamin C formulations
FI104407B (en) A process for preparing skin care compositions
EP1028723B1 (en) Stabilized ascorbic acid, composition, and method of use
KR100740393B1 (en) Minoxidil-Containing Preparations
EP1033985B1 (en) Stable ascorbic acid preparation for topical use
WO2002094251A1 (en) Compositions for the treatment of pigmentation disorders and methods for their manufacture
EP0982990B1 (en) Stable liquid calcium ascorbate compositions and methods of manufacture and use
CA2027964A1 (en) External skin preparation
KR100883229B1 (en) Composition containing vitamin c
US5037655A (en) Method of stabilizing tretinoin
KR100297347B1 (en) A W/O type emulsion cosmetic composition containing the stabilized L-ascorbic acid and a method for preparing the same
US4837213A (en) Pharmaceutical vehicle for active substances in the form of an anhydrous gel
US20070077261A1 (en) Compositions and method for enhancing the solubility of ascorbic acid using solubilization enhancers
JP3380261B2 (en) Cosmetics
CA1208552A (en) Storage stable topical pharmaceutical composition including nitrogen-containing stabilizers
KR20040085825A (en) Stable Liquid Composition Containing Vitamin C
JPS63156708A (en) Skin-beautifying agent
JPH11501633A (en) Pharmaceutical, cosmetic and / or food compositions having antioxidant properties
JP2002012535A (en) Composition for bleaching melamine
US20010003754A1 (en) Stable liquid mineral ascorbate compositions and methods of manufacture and use
MXPA99008759A (en) Stable liquid mineral ascorbate compositions and methods of manufacture and use
KR20040057411A (en) Non-water cosmetic product as powder type with high concentrated L-Ascorbic Acid and preparation method thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: IGEN, INC., DELAWARE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATHUR, RAJIV;REEL/FRAME:010118/0291

Effective date: 19990716

AS Assignment

Owner name: FLEET CAPITAL CORPORATION, CONNECTICUT

Free format text: SECURITY INTEREST;ASSIGNOR:IGEN, INC;REEL/FRAME:010639/0483

Effective date: 19991029

AS Assignment

Owner name: AMERICAN CAPITAL STRATEGIES, LTD., MARYLAND

Free format text: SECURITY INTEREST;ASSIGNOR:IGEN, INC.;REEL/FRAME:010776/0853

Effective date: 19991029

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
AS Assignment

Owner name: IGEN, INC., NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:FLEET CAPITAL CORPORATION;REEL/FRAME:022248/0477

Effective date: 20020531

AS Assignment

Owner name: LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) I

Free format text: SECURITY AGREEMENT;ASSIGNORS:IGI LABORATORIES, INC.;IMMUNOGENETICS, INC.;REEL/FRAME:022399/0576

Effective date: 20090313

Owner name: LIFE SCIENCES OPPORTUNITIES FUND II, L.P., NEW YOR

Free format text: SECURITY AGREEMENT;ASSIGNORS:IGI LABORATORIES, INC.;IMMUNOGENETICS, INC.;REEL/FRAME:022399/0576

Effective date: 20090313

AS Assignment

Owner name: IMMUNOGENETICS, INC., NEW JERSEY

Free format text: RELEASE OF SECURITY AGREEMENT RECORDED 3/16/09, R/F 02239/0570;ASSIGNORS:LIFE SCIENCES OPPORTUNITIES FUND II, L.P.;LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P.;REEL/FRAME:022708/0091

Effective date: 20090519

Owner name: IGI LABORATORIES INC., NEW JERSEY

Free format text: RELEASE OF SECURITY AGREEMENT RECORDED 3/16/09, R/F 02239/0570;ASSIGNORS:LIFE SCIENCES OPPORTUNITIES FUND II, L.P.;LIFE SCIENCES OPPORTUNITIES FUND (INSTITUTIONAL) II, L.P.;REEL/FRAME:022708/0091

Effective date: 20090519

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: IGEN, INC., NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:AMERICAN CAPITAL, LTD. (FORMERLY NAMED AMERICAN CAPITAL STRATEGIES, LTD.) AS GRANTEE;REEL/FRAME:034809/0553

Effective date: 20150120

AS Assignment

Owner name: CANTOR FITZGERALD SECURITIES, AS COLLATERAL AGENT,

Free format text: NOTICE OF GRANT;ASSIGNORS:TELIGENT, INC.;IGEN, INC.;TELIGENT PHARMA, INC.;REEL/FRAME:046286/0946

Effective date: 20180601

AS Assignment

Owner name: TELIGENT, INC, NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CANTOR FITZGERALD SECURITIES;REEL/FRAME:047800/0356

Effective date: 20181213

Owner name: IGEN, INC., NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CANTOR FITZGERALD SECURITIES;REEL/FRAME:047800/0356

Effective date: 20181213

Owner name: TELIGENT PHARMA, INC, NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CANTOR FITZGERALD SECURITIES;REEL/FRAME:047800/0356

Effective date: 20181213

Owner name: ARES CAPITAL CORPORATION, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNORS:TELIGENT, INC.;IGEN, INC.;REEL/FRAME:047800/0532

Effective date: 20181213

Owner name: ACF FINCO I LP, NEW YORK

Free format text: SECURITY INTEREST;ASSIGNORS:TELIGENT, INC;IGEN, INC.;REEL/FRAME:047800/0477

Effective date: 20181213